GlaxoSmithKline Pharmaceuticals Q2 net dips 25% at Rs 96 cr

By: |
New Delhi | Published: October 31, 2015 3:58:44 PM

GlaxoSmithKline Pharmaceuticals today reported a 25.39 per cent dip in standalone net profit at Rs 96.05 crore for the quarter ended September 30.

GlaxoSmithKline q2 profitEstablished in 1924 in India, GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines. (Reuters)

GlaxoSmithKline Pharmaceuticals today reported a 25.39 per cent dip in standalone net profit at Rs 96.05 crore for the quarter ended September 30.

The company had posted a net profit of Rs 128.67 crore for the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a filing to BSE.

Standalone total income from operations also declined to Rs 700.09 crore for the quarter under review as against Rs 746.76 crore for the corresponding period of previous fiscal.

Established in 1924 in India, GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines.

The firm’s prescription medicines range across therapeutic areas such as dermatology, anti-infectives, gynaecology, diabetes, cardiovascular diseases, respiratory diseases and oncology.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition